Physician profile
Diego Marin
NPI 1225484892
$3,053.51
in general payments reported to CMS, 2019-2025
20 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $331 · 2021: $336 · 2022: $192 · 2024: $1,370 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Consulting Fee: $525 · Education: $90.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.66 |
| Consulting Fee | $525.00 |
| Education | $90.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,030.14 | 2020-2025 | Tagrisso, Fasenra, Breztri |
| Allergan, INC. | $412.25 | 2019 | |
| Glaxosmithkline, LLC. | $343.75 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $161.08 | 2024 | Zephyr Endobronchial Valve |
| Ethicon INC. | $147.57 | 2024 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.68 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $132.32 | 2024 | Opsumit, Uptravi |
| Csl Behring | $127.92 | 2020-2021 | |
| Mylan Specialty L.P. | $124.73 | 2024 | Yupelri |
| Amgen INC. | $120.88 | 2019-2020 | |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.22 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $41.05 | 2022 | |
| Coaptech, INC. | $33.87 | 2025 | Puma System |
| Ani Pharmaceuticals, INC. | $29.01 | 2024 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $16.50 | 2020 | |
| Pfizer INC. | $15.00 | 2020 | |
| Akcea Therapeutics, INC. | $14.19 | 2020 | |
| Circassia INC. | $13.85 | 2019 | |
| Genzyme Corporation | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Marin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.